Literature DB >> 17900243

Methylprednisolone injection via the portal vein suppresses inflammation in acute liver failure induced in rats by lipopolysaccharide and d-galactosamine.

Nobito Higuchi1, Masaki Kato, Kazuhiro Kotoh, Motoyuki Kohjima, Shinichi Aishima, Makoto Nakamuta, Yoshinori Fukui, Ryoichi Takayanagi, Munechika Enjoji.   

Abstract

BACKGROUND: We have reported that hepatic arterial steroid injection is an effective therapy to rescue patients from fulminant or severe acute hepatic failure. We speculate that a high concentration of steroid suppresses inflammatory processes in the liver directly by restraining activated inflammatory cells, including macrophages. To analyse the detailed mechanism, steroid injection via the portal vein was performed in an experimental model of liver damage.
METHODS: Rats subjected to lipopolysaccharide and d-galactosamine injection were treated with a methylprednisolone injection via the tail vein or the portal vein. The survival rate, serum levels of inflammatory cytokines and apoptotic cell counts in the liver were analysed.
RESULTS: The survival rate was significantly improved by steroid injection, especially via the portal vein. Serum values of alanine aminotransferase, tumor necrosis factor-alpha and interferon-gamma were reduced in the treated groups, especially the group given portal venous injections. Apoptotic cell counts in the liver were significantly lower in the group injected with steroid via the portal vein.
CONCLUSION: In the model rats, high concentrations of steroid in the liver acted on inflammatory cells and suppressed inflammatory cytokines and liver cell death. The mechanism is suggested to be the same for arterial steroid injection therapy in patients with acute hepatic failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900243     DOI: 10.1111/j.1478-3231.2007.01590.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

1.  Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.

Authors:  Nami Mori; Fumitaka Suzuki; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saito; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2012-02-29       Impact factor: 7.527

2.  Evaluation of the efficacy of steroid therapy on acute liver failure.

Authors:  Bo Zhao; Hui-Yan Zhang; Gui-Juan Xie; Hui-Min Liu; Qing Chen; Rui-Feng Li; Jian-Ping You; Sha Yang; Qing Mao; Xu-Qing Zhang
Journal:  Exp Ther Med       Date:  2016-09-20       Impact factor: 2.447

3.  Decreases in activated CD8+ T cells in patients with severe hepatitis B are related to outcomes.

Authors:  Yinong Ye; Jing Liu; Qing Lai; Qiyi Zhao; Liang Peng; Chan Xie; Genglin Zhang; Shaoquan Zhang; Yufeng Zhang; Jianyun Zhu; Yangsu Huang; Zhaoxia Hu; Dongying Xie; Bingliang Lin; Zhiliang Gao
Journal:  Dig Dis Sci       Date:  2014-08-01       Impact factor: 3.199

4.  Antithrombin III injection via the portal vein suppresses liver damage.

Authors:  Masayuki Miyazaki; Masaki Kato; Masatake Tanaka; Kosuke Tanaka; Shinichiro Takao; Motoyuki Kohjima; Tetsuhide Ito; Munechika Enjoji; Makoto Nakamuta; Kazuhiro Kotoh; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

5.  The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial.

Authors:  Lin Jia; Ran Xue; Yueke Zhu; Juan Zhao; Juan Li; Wei-Ping He; Xiao-Mei Wang; Zhong-Hui Duan; Mei-Xin Ren; Hai-Xia Liu; Hui-Chun Xing; Qing-Hua Meng
Journal:  BMC Med       Date:  2020-12-08       Impact factor: 8.775

Review 6.  Glucocorticoid Treatment Strategies in Liver Failure.

Authors:  Chao Ye; Wenyuan Li; Lei Li; Kaiguang Zhang
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.